The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InEli Lilly has officially announced a definitive agreement to acquire Kelonia Therapeutics in a deal valued at up to $7 billion, featuring an upfront cash payment of $3.25 billion. Through this acquisition, Lilly secures the proprietary iGPS platform designed to modify T-cells directly inside the body. Analysts at UBS view the acquisition as a positive step for long-term pipeline building, noting the strategic value of the technology. Notably, the deal ranks among the largest to date in the specialized in vivo CAR-T therapy space. This move underscores Lilly's commitment to diversifying its portfolio beyond its core weight-loss and diabetes franchises. The transaction includes the lead program KLN-1010, currently in Phase 1 trials for multiple myeloma. Investors are now evaluating how this significant capital deployment will shape the firm's long-term competitive edge in oncology.